Rockland Trust Co. Sells 4,859 Shares of Thermo Fisher Scientific Inc. $TMO

Rockland Trust Co. cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 59,133 shares of the medical research company’s stock after selling 4,859 shares during the period. Thermo Fisher Scientific makes up 1.3% of Rockland Trust Co.’s investment portfolio, making the stock its 20th largest position. Rockland Trust Co.’s holdings in Thermo Fisher Scientific were worth $34,265,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of TMO. JPL Wealth Management LLC bought a new stake in Thermo Fisher Scientific in the third quarter valued at approximately $28,000. Highline Wealth Partners LLC boosted its position in shares of Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after purchasing an additional 33 shares in the last quarter. Beacon Financial Strategies CORP acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $29,000. Olistico Wealth LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $29,000. Finally, Capital A Wealth Management LLC raised its stake in Thermo Fisher Scientific by 825.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after buying an additional 66 shares during the period. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on TMO shares. UBS Group reissued a “neutral” rating and issued a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Barclays lifted their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, January 30th. DZ Bank began coverage on Thermo Fisher Scientific in a research note on Friday, March 27th. They set a “buy” rating and a $610.00 target price for the company. Wells Fargo & Company set a $683.00 target price on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Finally, Stifel Nicolaus upped their price target on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $632.50.

Thermo Fisher Scientific Stock Up 2.5%

TMO stock opened at $492.07 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. The stock has a market capitalization of $182.80 billion, a P/E ratio of 27.74, a P/E/G ratio of 2.77 and a beta of 0.96. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The business has a 50-day moving average of $524.79 and a 200-day moving average of $548.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same quarter last year, the firm earned $6.10 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 7.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th will be given a $0.47 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, March 13th. Thermo Fisher Scientific’s payout ratio is presently 10.60%.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the transaction, the executive vice president owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. The trade was a 3.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher launched the Thermo Scientific Glacios 3 Cryo-TEM, a next‑generation 200 kV cryo‑TEM targeted at structural biology labs — a product that can expand addressable markets for high‑margin instruments and support equipment sales and service revenue growth. Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM
• Positive Sentiment: Positive investor commentary and momentum from recent quarterly results (strong EPS and revenue beat in late Jan.) have helped set expectations for a rally and a new 52‑week high, reinforcing investor confidence in execution and cash flow. Thermo Fisher Scientific (TMO) Sets Stage for Q4 Rally with Impressive Q3 Earnings and New 52-Week High
• Positive Sentiment: High‑profile endorsement: media coverage noting Jim Cramer called the company “unbelievable” has driven retail interest and contributed to the stock’s upward momentum, especially given TMO’s exposure to the booming biopharma/GLP‑1 supply chain. Thermo Fisher (TMO) Shares Up Since Jim Cramer Called the Firm “Unbelievable”
• Neutral Sentiment: Research coverage initiated at DZ Bank — adds institutional coverage and may improve liquidity and analyst visibility; impact depends on the tone of subsequent reports. Thermo Fisher Scientific (NYSE:TMO) Research Coverage Started at DZ Bank
• Negative Sentiment: Industry cost risk: multiple outlets cite analyst concerns that rising global helium prices (linked to geopolitical tensions) could increase operating costs for cryogenic instruments and consumables — a potential margin headwind for TMO’s instrument/service businesses. How is Thermo Fisher (TMO) Preparing to Deal With Rising Helium Prices
• Negative Sentiment: Small position trim: Beacon Investment Advisory sold 1,296 shares in Q4, shrinking its holding — a minor vote of caution but not material to TMO’s large shareholder base. Beacon Investment Advisory Services Inc. Sells 1,296 Shares of Thermo Fisher Scientific Inc. $TMO

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.